Rocket Pharmaceuticals, Inc.

DB:9IP1 Stock Report

Market Cap: €1.1b

Rocket Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:9IP1 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Nov 24Sell€138,021Gaurav ShahIndividual11,091€12.44
21 Nov 24Sell€14,622Martin WilsonIndividual1,175€12.44
21 Nov 24Sell€15,232John MilitelloIndividual1,224€12.44
21 Nov 24Sell€57,095Kinnari PatelIndividual4,588€12.44
31 Oct 24Sell€14,041John MilitelloIndividual917€15.31
31 Oct 24Sell€47,160Mark WhiteIndividual3,080€15.31
16 Aug 24Sell€67,155Kinnari PatelIndividual3,989€16.83
16 Aug 24Sell€17,289Martin WilsonIndividual1,027€16.83
16 Aug 24Sell€162,457Gaurav ShahIndividual9,650€16.83
16 Aug 24Sell€17,912John MilitelloIndividual1,064€16.83
22 Jul 24Sell€17,171John MilitelloIndividual812€21.15
08 Jul 24Sell€56,963Mark WhiteIndividual3,026€18.82
16 May 24Sell€22,513Martin WilsonIndividual1,048€21.48
16 May 24Sell€23,179John MilitelloIndividual1,079€21.48
16 May 24Sell€86,916Kinnari PatelIndividual4,046€21.48
16 May 24Sell€210,309Gaurav ShahIndividual9,790€21.48
22 Apr 24Sell€17,898John MilitelloIndividual833€21.49
15 Apr 24Sell€226,209David SouthwellIndividual10,000€22.62
08 Apr 24Sell€284,433Mark WhiteIndividual12,532€22.70
21 Mar 24Sell€64,444John MilitelloIndividual2,490€25.88
21 Mar 24Sell€7,174,680Simran Investment Group LlcCompany274,000€26.18
29 Feb 24Sell€111,250Martin WilsonIndividual4,100€27.13
16 Feb 24Sell€561,446Gaurav ShahIndividual20,272€27.70
16 Feb 24Sell€89,678John MilitelloIndividual3,238€27.70
16 Feb 24Sell€99,040Martin WilsonIndividual3,576€27.70
16 Feb 24Sell€197,525Kinnari PatelIndividual7,132€27.70
22 Jan 24Sell€15,938John MilitelloIndividual638€24.98

Insider Trading Volume

Insider Buying: 9IP1 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 9IP1?
Owner TypeNumber of SharesOwnership Percentage
Private Companies104,9270.106%
Individual Insiders2,224,3222.25%
Hedge Funds18,188,45718.4%
Institutions78,486,66879.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 84.65% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20%
RTW Investments, LP
18,188,457€219.9m2.83%3.24%
12.3%
Wellington Management Group LLP
11,242,144€135.9m22.8%0.02%
6.99%
BlackRock, Inc.
6,370,721€77.0m2.88%no data
6.07%
The Vanguard Group, Inc.
5,536,940€66.9m-4.68%no data
4.93%
Westfield Capital Management Company, L.P.
4,493,833€54.3m3.83%0.24%
4.52%
Maverick Capital, Ltd.
4,118,672€49.8m4.85%0.92%
3.52%
T. Rowe Price Group, Inc.
3,207,781€38.8m1.21%no data
3.4%
State Street Global Advisors, Inc.
3,102,022€37.5m11.6%no data
2.36%
Citadel Advisors LLC
2,148,093€26.0m-23.8%0.03%
2.08%
Janus Henderson Group plc
1,897,340€22.9m-35%0.01%
1.77%
Geode Capital Management, LLC
1,617,866€19.6m0.89%no data
1.63%
Frazier Life Sciences Management, LP
1,485,630€18.0m-4.84%0.71%
1.61%
Tavistock Life Sciences
1,466,051€17.7m0%1.27%
1.52%
Pictet Asset Management Limited
1,386,705€16.8m13.1%0.02%
1.32%
Millennium Management LLC
1,202,495€14.5m1,040%0.01%
1.22%
Gaurav Shah
1,113,566€13.5m-0.99%no data
1.21%
Novo Holdings A/S
1,100,000€13.3m0%0.01%
1.21%
Cowen Inc,Private Banking and Investment Banking Investments
1,100,000€13.3m0%0.38%
1.17%
BioImpact Capital LLC
1,066,373€12.9m0%2.25%
1.06%
Franklin Resources, Inc.
969,547€11.7m-13.2%no data
1.02%
Perceptive Advisors LLC
931,851€11.3m-25.3%0.27%
1%
Dimensional Fund Advisors LP
912,605€11.0m-3.55%no data
0.97%
Baron Capital Group, Inc.
884,341€10.7m-9.7%0.03%
0.89%
Russell Investment Management, LLC
812,310€9.8m19.9%0.01%
0.89%
Medical Strategy GmbH, Asset Management Arm
808,816€9.8m0%0.61%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 14:51
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Gregory HarrisonBofA Global Research
Yun ZhongBTIG